CARsgen seeks cell therapy breakthrough but stays in the red for now
The developer of specialized cancer treatments is shifting from costly personalized therapy to more standardized options, but at the price of short-term financial pain Key Takeaways: The company launched its…
FAST NEWS: JW Therapeutics to expand collaboration with 2Seventy Bio
The latest: Drug maker JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Tuesday it is in talks to expand its strategic alliance with 2Seventy Bio (TSVT.US), which began with a partnership established in…
FAST NEWS: JW Therapeutics’ loss narrows on lower selling expenses
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) reported on Tuesday its net loss for the first half of 2023 narrowed 11.4% year-on-year to 380 million yuan ($52.1 million). Looking…
FAST NEWS: JW Therapeutics’ revenue soars on growing lymphoma drug sales
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Wednesday its revenue surged 373% to 146 million yuan ($21.2 million) last year, while its non-GAAP net loss narrowed…
No Early Relief for JW Therapeutics from Cancer Wonder Drug
The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices…
FAST NEWS: JW Therapeutics Announces Two Major Senior Appointments
The latest: Immunotherapy products maker JW (Cayman) Therapeutics Co. Ltd. (2126.HK) announced two major new appointments, including Dr. Shaun Paul Cordoba as its chief scientific officer and Raymond J. Hage…
Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited Key takeaways: • Less than…
